These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36830273)

  • 1. Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.
    Wang X; Xiong L; Yu W; Huang C; Ji J; Ying C; Liu Z; Chen Y; Xiao Y
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of Ceftazidime/Avibactam Administration in
    Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
    Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Gill CM; Nicolau DP;
    Clin Ther; 2023 Jan; 45(1):72-77. PubMed ID: 36593150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR; Burgess DS
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
    Eagye KJ; Nicolau DP; Lockhart SR; Quinn JP; Doern GV; Gallagher G; Abramson MA
    Ann Clin Microbiol Antimicrob; 2007 Oct; 6():11. PubMed ID: 17908321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK; Grupper M; Nicolau DP; Kuti JL
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulating moxalactam dosage for extended-spectrum β-lactamase-producing
    Huang C; Shi Q; Zheng B; Ji J; Ying C; Yu X; Wang H; Xiao Y
    Infect Drug Resist; 2019; 12():1199-1208. PubMed ID: 31190908
    [No Abstract]   [Full Text] [Related]  

  • 10. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection.
    Zhu W; Chu Y; Zhang J; Xian W; Xu X; Liu H
    Microb Pathog; 2020 Jan; 138():103809. PubMed ID: 31634531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
    Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
    Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
    Eagye KJ; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2007 Apr; 8(2):215-26. PubMed ID: 17437367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.